ES406590A1 - Procedimiento para la vacunacion preventiva contra viruela. - Google Patents

Procedimiento para la vacunacion preventiva contra viruela.

Info

Publication number
ES406590A1
ES406590A1 ES406590A ES406590A ES406590A1 ES 406590 A1 ES406590 A1 ES 406590A1 ES 406590 A ES406590 A ES 406590A ES 406590 A ES406590 A ES 406590A ES 406590 A1 ES406590 A1 ES 406590A1
Authority
ES
Spain
Prior art keywords
contg
vaccinia virus
attenuated vaccinia
smallpox vaccine
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES406590A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BAYERN FREISTAAT
Original Assignee
BAYERN FREISTAAT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712145477 external-priority patent/DE2145477C3/de
Application filed by BAYERN FREISTAAT filed Critical BAYERN FREISTAAT
Publication of ES406590A1 publication Critical patent/ES406590A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES406590A 1971-09-11 1972-09-11 Procedimiento para la vacunacion preventiva contra viruela. Expired ES406590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19712145477 DE2145477C3 (de) 1971-09-11 Impfstoff für die intracutane Pockenschutzimpfung

Publications (1)

Publication Number Publication Date
ES406590A1 true ES406590A1 (es) 1975-09-16

Family

ID=5819271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES406590A Expired ES406590A1 (es) 1971-09-11 1972-09-11 Procedimiento para la vacunacion preventiva contra viruela.

Country Status (5)

Country Link
AT (1) AT320149B (enExample)
BE (1) BE787901A (enExample)
CH (1) CH568392A5 (enExample)
DK (1) DK137392C (enExample)
ES (1) ES406590A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO2004015118A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
WO2004087201A2 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
EP2152862A1 (en) 2007-05-14 2010-02-17 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
JP2013507107A (ja) 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2017120577A1 (en) 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4358999A1 (en) 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein

Also Published As

Publication number Publication date
DE2145477B2 (de) 1976-04-01
AT320149B (de) 1975-01-27
DK137392C (da) 1978-09-18
DK137392B (da) 1978-02-27
DE2145477A1 (de) 1973-03-15
CH568392A5 (enExample) 1975-10-31
BE787901A (fr) 1972-12-18

Similar Documents

Publication Publication Date Title
ES406590A1 (es) Procedimiento para la vacunacion preventiva contra viruela.
GB1501724A (en) Highly attenuated cytomegalovirus vaccine and production thereof
AU3475271A (en) Face steamer
CA924330A (en) High purity hot pressed boron nitride
ES426215A1 (es) Procedimiento para preparar una vacuna de adenovirus bovi- nos vivos.
CA970110A (en) Low-froth, water-soluble dyeing auxiliaries
CA970109A (en) Low-froth, water-soluble dyeing auxiliaries
CA956130A (en) Steam pressure cooker
SE417097B (sv) 2,4 diamino-5 bensylpyrimidiner till anvendning som mellanprodukter for framstellning av 2,4 diamino-5 bensylpyrimidiner och sett att framstella dem
CA949408A (en) Steam boiler
AU451635B2 (en) Vaccine preparation
SU77221A1 (ru) Терморегул тор, преимущественно дл муфельной печи
DK134987B (da) Fremgangsmåde til fremstilling af 4,4'-ditert.-butyl-benzoylperoxid.
CA952169A (en) Skin heating of steel by a.c.
CA943458A (en) Process for producing anhydrous smallpox vaccine
ZA729156B (en) Vaccine adjuvants
DK134518B (da) Analogifremgangsmåde til fremstilling af 4beta-alkoxy-4alfa-(3'-hydroxyphenyl)-3alfa,5alfa-propanopiperidin-derivater.
DK133243C (da) 2,4-diamino-5-benzyl-6-thiopyrimidiner til anvendelse som mellemprodukter og fremgangsmade til deres fremstilling
Ohmura et al. 91Zr (p, t) 89Zr Reaction at 51.7 MeV
CA957892A (en) Cultivator
CA875366A (en) Steam cooled gas turbine
CA638733A (en) Pressure steam cookers
CA884853A (en) Vaccine for equine influenza
CA866998A (en) Integral vapor generator-nuclear reactor
AU442172B2 (en) Diethylaminoethyldextran (dead-d) as adjuvant for vaccines for active immunisation